Tue, Sep 30, 2014, 12:53 PM EDT - U.S. Markets close in 3 hrs 7 mins

Recent

% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

hwmccusker 5 posts  |  Last Activity: Sep 18, 2014 1:20 PM Member since: Jan 8, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Dominick Colangelo, CEO – 20 K shares at $2.55 per share = $51 K (0.12% of latest offering)
    Michel Gerard, CFO – 20 K shares at $2.55 per share = $51 K (0.12% of latest offering).
    Daniel Orlando, CFO – 9,804 shares at $2.55 per share =$25 K (0.6% of latest offering).
    The Bottom Line: A measly amount of purchase considering the compensation levels. “Skin in the game” is a joke considering Colangelo’s 2013 total compensation was $1.4 M, Orlando’s 2013 total compensation was $585 K, and Gerard’s 2014 total compensation is estimated at $500 K+.

    Sentiment: Strong Sell

  • A question of ASTM’s 13.7 share offering at $2.55 – how MUCH of the offering was BOUGHT by the CEO, officers and Board of Directors?
    My bet ... barely or if ANYTHING! Let’s see how it closes on 9/16/14 and the quarterly filings?

    Sentiment: Strong Sell

  • But, this Board of Directors who have direct responsibility for representing shareholders or those who might be interested in its financial stability. In Aastrom’s (ASTM) case – that responsibility, respect and representation appears NOT to EXIST!
    Even if and when this offering gets completed … the representation of investors has been so diminished … the repugnance will linger for more than a LONG time!
    I quote from … The Bottom Line by Carl Icahn … “I believe that too many companies in this country are terribly run and there’s no system in place to hold the CEOs and Boards of these inadequately managed companies accountable!”
    I’ve made my case hopefully investors will LISTEN?

    Sentiment: Strong Sell

  • The “word” is the Aastrom (ASTM) offering of $35 M (???) has been ... PUT OFF until ... WEDNESDAY for PRICING in a strictly institutional DEAL – i.e. ONE CLIENT??
    After the entire scenario of meetings and hullabaloo … NO ONE STEPPED UP!
    In the military they call it … "No JOY” i.e. … ASTM has been unsuccessful! ... TODAY (?). Is there a lesson … disclosure and rapport with investors!. Also MIGHT someone be PROTECTING their INVESTMENT!

    Sentiment: Strong Sell

  • UP +$0.27 to $3.91. Many traders will be “whacking” these numbers while their 3 ATM “temporary holders” will be selling into the appreciation to REDUCE their … positions

    READ ... the “study limitations” in the “published” paper!!

    Just ANOTHER case of selective DISCLOSURE – SELL!

    ASTM had their P2a clinical studies of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM) published in the peer-reviewed journal Circulation Research.
    In an article entitled "Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy," results showed that treatment with ixmyelocel-T reduced the incidence of major adverse cardiovascular events (MACE) in patients with ischemic DCM.

    • In 2 separate open-label studies, a total of 61 patients were randomized and
    • 59 were treated or received standard of care. The combined results among ischemic DCM patiendemonstrated that patients treated with ixmyelocel-T experienced fewer MACE events during follow up compared to control patients.

    Heart failure (HF) exacerbation was the most common MACE. Relative to the control patients, ischemic DCM patients treated with ixmyelocel-T also experienced an improvement in symptoms as measured by the New York Heart Association classification system.

    The Bottom Line: The P2b trial replicated … PREVIOUS results. However, they are INSIGNIFICANT for such a small study which is just REITERATING a safety trial which always seems to be EFFECTIVE particularly when using the body’s own cells ! What are the statistics for comparison?
    Read the "Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy,"

    A couple of observations: Open label – only people getting therapy had a bone marrow aspirate and underwent a catheter procedure (i.e.: the patient and doctors know). With very small numbers, a few events either way changed the outcome –

    Sentiment: Strong Sell

SVFC
0.0010.000(0.00%)12:36 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.